The effect of β-1,3-glucan derived from Euglena gracilis (Algamune™ ) on the innate immunological responses of Nile tilapia (Oreochromis niloticus L.)
© 2018 John Wiley & Sons Ltd.
| Veröffentlicht in: | Journal of fish diseases. - 1998. - 41(2018), 10 vom: 27. Okt., Seite 1579-1588 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2018
|
| Zugriff auf das übergeordnete Werk: | Journal of fish diseases |
| Schlagworte: | Journal Article Euglena gracilis biological modifier immunostimulant Adjuvants, Immunologic Reactive Oxygen Species beta-Glucans Superoxides 11062-77-4 beta-1,3-glucan |
| Zusammenfassung: | © 2018 John Wiley & Sons Ltd. Algamune™ is a commercial additive produced from Euglena gracilis, providing a rich source of the β-1,3-glucan paramylon. Isolated kidney phagocytes of Nile tilapia were incubated with graded doses (0, 8, 16, 32, 64 and 128 μg/ml) of Algamune™ and purified paramylon to gauge their ability to elicit the production of reactive oxygen species. A linear response was observed for extracellular superoxide anion for both sources but only Algamune™ for intracellular superoxide anion. After corroborating the immunostimulant properties ex vivo, a feeding trial was conducted to evaluate the dietary supplementation of Algamune™ (0, 100, 200, 400 and 800 mg/kg of diet) for Nile tilapia. Fish were fed for 3 weeks, after which, fish were sampled for blood and head kidney phagocytes. The remaining fish were challenged with Streptococcus iniae. Macrophage extracellular superoxide anion production was significantly elevated in fish fed diets with 200 mg of Algamune™ kg-1 when compared to fish fed the basal diet. Even though the disease challenge did not show statistical differences, it is worth mentioning that fish fed intermediate doses of Algamune™ had lowest numerical mortality values. Therefore, Algamune™ was demonstrated to enhance some immunological responses of tilapia both in ex vivo and in vivo |
|---|---|
| Beschreibung: | Date Completed 30.01.2019 Date Revised 30.09.2020 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1365-2761 |
| DOI: | 10.1111/jfd.12871 |